Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index-Reference-Cited by-同舟云学术

Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index

Author:

Bonadonna Riccardo C.¹^ORCID,Blonde Lawrence²,Antsiferov Mikhail³,Berria Rachele⁴,Gourdy Pierre⁵,Hatunic Mensud⁶,Mohan Viswanathan⁷,Horowitz Michael⁸

Affiliation:

1. University of Parma and Azienda Ospedaliero-Universitaria di Parma; Parma Italy

2. Frank Riddick Diabetes Institute; Department of Endocrinology, Ochsner Medical Center; New Orleans LA USA

3. Moscow Department of Health Care; Moscow Russian Federation

4. Sanofi; Bridgewater NJ USA

5. Diabetology Department; Toulouse University Hospital; Toulouse France

6. Department of Endocrinology; Mater Misericordiae University Hospital; Dublin Ireland

7. Madras Diabetes Research Foundation & Dr Mohan's Diabetes Specialities Centre; Chennai India

8. Royal Adelaide Hospital; Adelaide Australia

Funder

This study was sponsored by Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference50 articles.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献